Australia - English - Department of Health (Therapeutic Goods Administration)

paragon medical pty ltd trading as lr instruments richards medical -

Australia - English - Department of Health (Therapeutic Goods Administration)

paragon medical pty ltd trading as lr instruments richards medical -

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - prucalopride succinate, quantity: 1.321 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin; macrogol 3000 - resotrans is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief -before resotrans is considered, patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. - if treatment with resotrans is not effective within four weeks, the benefit of continuing treatment should be reconsidered

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - prucalopride succinate, quantity: 2.642 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3000; indigo carmine aluminium lake - resotrans is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief -before resotrans is considered, patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. - if treatment with resotrans is not effective within four weeks, the benefit of continuing treatment should be reconsidered

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gw pharma ltd - cannabidiol; dronabinol - spray - 2.5mg/1dose ; 2.7mg/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - prucalopride succinate - tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - prucalopride succinate - tablet - 2mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

birzeit pharmaceutical company (bpc) - clobetasol (clobetasol propionate) - solution for topical use - 0,5mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

spectrum surgical pty ltd - 57950 - ophthalmic ultraviolet phototherapy system - the instrument is designed to be used exclusively for treatment of disorders of the cornea, in an ophthalmologic clinical setting and only by expert specialized physicians. the emitter is especially useful in treatment of keratoconus by corneal collagen cross-linking.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - prucalopride succinate -